Abstract N,N-Diallyltryptamine (DALT) and 5-methoxy-DALT (5-MeO-DALT) are synthetic tryptamine derivatives commonly referred to as so-called new psychoactive substances (NPS). They have psychoactive effects that may be similar to those of other tryptamine derivatives. The objectives of this work were to study the metabolic fate and detectability, in urine, of DALT and 5-MeO-DALT. For metabolism studies, rat urine obtained after high-dose administration was prepared by precipitation and analyzed by liquid chromatographyhigh-resolution mass spectrometry (LC-HR-MS-MS). On the basis of the metabolites identified, several aromatic and aliphatic hydroxylations, N-dealkylation, N-oxidation, and combinations thereof are proposed as the main metabolic pathways for both compounds. O-Demethylation of 5-MeO-DALT was also observed, in addition to extensive glucuronidation or sulfation of both compounds after phase I transformation. The cytochrome P450 (CYP) isoenzymes predominantly involved in DALT metabolism were CYP2C19, CYP2D6, and CYP3A4; those mainly involved in 5-MeO-DALT metabolism were CYP1A2, CYP2C19, CYP2D6, and CYP3A4. For detectability studies, rat urine was screened by GC-MS, LC-MS n , and LC-HR-MS-MS after administration of low doses. LC-MS n and LC-HR-MS-MS were deemed suitable for monitoring consumption of both compounds. The most abundant targets were a ring hydroxy metabolite of DALT, the N,O-bis-dealkyl metabolite of 5-MeO-DALT, and their glucuronides. GC-MS enabled screening of DALT by use of its main metabolites only.
Introduction
Synthetic tryptamines belong to new psychoactive substances (NPS), a class which also includes synthetic cannabinoids, phenethylamines, synthetic cathinones, and others [1, 2] . They interact with the serotonergic system, resulting in activation of 5-HT 1A and 5-HT 2A receptor subtypes [3] and increased serotonin release [4] [5] [6] [7] [8] . It has been suggested that active oral doses of N,N-diallyltryptamine (DALT) and 5-methoxy-DALT (5-MeO-DALT) range from >40 mg for DALT and from 12-20 mg for 5-MeO-DALT [9] [10] [11] . Their chemical structures are depicted in Fig. 1 . The control status of both substances differs across the globe. Misuse of 5-MeO-DALT and its association with adverse effects have recently been reported [12, 13] ; this serves as a reminder that the ability to perform suitable toxicological analysis is urgently needed. No data are available on misuse of DALT.
Analytical methods used for characterization of N,Ndialkylated tryptamines [14] and naturally-occurring N,NElectronic supplementary material The online version of this article (doi:10.1007/s00216-015-8955-0) contains supplementary material, which is available to authorized users. dimethylated tryptamines found in psychoactive beverages [15] have been reviewed but without reference to determination in biofluids. Information on metabolism in urine is important so that appropriate targets can be identified. Katagi et al. reviewed the general metabolic steps and toxicological analysis of several 5-methoxy-N,N-dialkyltryptamines [16] . Metabolism and detectability of DALT and 5-MeO-DALT in relevant matrices have not yet been reported. Therefore, the purpose of this work was to identify phase I and II metabolites of DALT and 5-MeO-DALT in rat urine and in pooled human liver microsomes (pHLM) by liquid chromatography (LC)-high resolution (HR)-MS-MS and to identify the human cytochrome-P450 (CYP) isoenzymes involved in the main metabolic steps. The detectability of DALT and 5-MeO-DALT in urine by use of the authors' GC-MS, LC-MS n , and LC-HR-MS-MS standard urine-screening approaches (SUSA) was tested.
Experimental Chemicals and reagents
DALT, DALT-d 4 , and 5-MeO-DALT were synthesized by use of established methods [17] . Isocitrate and isocitrate dehydrogenase were from Sigma (Taufkirchen, Germany), NADP + from Biomol (Hamburg, Germany), acetonitrile (LC-MS grade), ammonium formate (analytical grade), formic acid (LC-MS grade), methanol (LC-MS grade), and all other chemicals and biochemicals from VWR (Darmstadt, Germany). Baculovirus-infected insect cell microsomes (Supersomes) containing 1 nmol mL −1 human cDNAexpressing CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 (2 nmol mL −1 ), CYP3A4, and CYP3A5 (2 nmol mL −1
), and pooled human liver microsomes (pHLM; 20 mg microsomal protein mL −1 , 400 pmol total CYP mg −1 protein) were obtained from BD Biosciences (Heidelberg, Germany). After delivery, the microsomes were thawed at 37°C, divided into aliquots, snapfrozen in liquid nitrogen, and stored at −80°C until use.
Urine
Investigations were performed on rat urine from male Wistar rats (Charles River, Sulzfeld, Germany) for toxicological diagnostic reasons. Compounds were administered once in an aqueous suspension by gastric intubation in a single 20 mg kg −1 body mass (BM) dose for identification of the metabolites and once in a single 1 mg kg −1 BM dose for toxicological analysis, in accordance with the German animal-protection act. The rats were housed in metabolism cages for 24 h, with water ad libitum. Urine was collected separately from feces over a 24-h period. Blank urine was collected before drug administration to confirm the absence of interfering compounds. The samples were directly analyzed and then stored at −20°C.
Sample preparation for identification of phase I and II metabolites by LC-HR-MS-MS As described elsewhere [18] , 500 μL acetonitrile was added to 100 μL urine. The mixture was shaken on a rotary shaker for 2 min. After centrifugation for 2 min at 10,000×g, 500 μL was transferred to a glass vial and evaporated to dryness under a gentle stream of nitrogen at 70°C. The residue was dissolved in 50 μL methanol then 10 μL was injected for LC-HR-MS-MS analysis.
Microsomal incubations for pHLM and initial CYP activity screening studies
The conditions used for microsomal incubation of each isomer have been published elsewhere [19] . Briefly, drugs (50 μmol L −1 ) were incubated with the CYP isoenzymes (50 pmol mL −1 ) CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, or CYP3A5, or pHLM (1 mg protein mL −1 ) for 30 min.
Reactions were initiated by addition of the substrate and stopped by addition of 50 μL ice-cold acetonitrile containing DALT-d 4 (1 mg L −1
) as internal standard. The solution was centrifuged for 2 min at 10,000×g, 50 μL of the supernatant phase was transferred to a glass vial, and 10 μL was injected for LC-HR-MS-MS analysis. 
LC-HR-MS-MS apparatus for identification of phase I and II metabolites in urine and microsomal incubations
In accordance with published procedures [20] , the extracts were analyzed by use of a Accela LC system consisting of an HTC PAL autosampler, a degasser, two 1250 quaternary pumps, an Aria Transcend TLX-I HTLC system, and a valve interface module with built-in switching valves, all controlled by Aria software version 1.6.3, coupled to a Q-Exactive system equipped with a heated electrospray ionization (HESI)-II source and Xcalibur 2.2 SP1.48 software (all from ThermoFisher, Dreieich, Germany). Mass calibration was conducted in accordance with the manufacturer's recommendations every 72 h, by external mass calibration. In accordance with Helfer et al. (submitted for publication), the LC conditions were: ThermoFisher Accucore phenylhexyl column (100 mm×2.1 mm I.D., 2.6 μm), guarded by a UHP filter cart (0.5 μm). Chromatography was performed at 35°C maintained by an analytical column heater (HotDog 5090; Prolab, Reinach, Switzerland). The mobile phases were 2 mmol L 
GC-MS SUSA
In accordance with published procedures [21] , urine (5 mL) was divided into two aliquots. One part was submitted to acid hydrolysis followed by extraction of the combined parts with dichloromethane-isopropanol-ethyl acetate. After evaporation, the residue was acetylated with acetic anhydride-pyridine under microwave irradiation, again evaporated, and reconstituted in 100 μL methanol. One microliter was injected for GC-MS analysis. The equipment consisted of a HewlettPackard (HP; Agilent, Waldbronn, Germany) 5890 Series II gas chromatograph combined with an HP 5972A MSD mass spectrometer and an HP MS ChemStation (DOS series) with HP G1034C software version C03.00. The GC conditions were: splitless injection mode; column, ThermoFisher TG-1MS capillary (12 m×0.2 mm I.D.); cross-linked methyl silicone, 330 nm film thickness; injection port temperature, 280°C; carrier gas, helium; flow rate, 1 mL min
; column temperature, programmed from 100 to 310°C at 30°min −1 ; initial time, 2 min; final time, 5 min. The MS conditions were: full-scan mode, m/z 50-550; electron ionization (EI) mode, ionization energy, 70 eV; ion source temperature, 220°C; and capillary direct interface, 280°C [22] .
The full-scan data files were evaluated by use of the automated mass spectral deconvolution and identification system (AMDIS) (http://chemdata.nist.gov/mass-spc/amdis/) in simple mode. The target library was a modified version of the Maurer/Pfleger/Weber MPW_2015 library [23] . The deconvolution settings were [24] : width, 32; adjacent peak subtraction, 2; resolution, high; sensitivity, very high; shape requirements, low; minimum match factor, 50.
LC-MS
n SUSA
The workup was identical with the procedure described above for identification of phase I and II metabolites. Analysis was performed with a LXQ linear ion trap MS equipped with an HESI II source and coupled to an Accela LC system (all from ThermoFisher). The LC and the MS settings have been described elsewhere [18] . Briefly, DDA was conducted on precursor ions selected from MS 1 : MS 1 was performed in the fullscan mode (m/z 100-800) and MS 2 and MS 3 were performed in the DDA mode. ThermoFisher Xcalibur 2.2 SP1.48 software was used for data acquisition, NIST MS Search 2.0 (National Institute of Standards and Technology, Gaithersburg, MD, USA) for library generation, and ThermoFisher ToxID 2.1.1 for automatic target screening in the MS 2 screening mode. The settings were: retention time (RT) window, 20 min; RT, 0.1 min; signal threshold, 100; search index, 600; and reverse search index, 700. ToxID was run automatically after file acquisition, by using a Xcalibur processing method starting the software tool. The target library was a modified version of the Maurer/Wissenbach/ Weber MWW_2014 library [25] .
LC-HR-MS-MS SUSA
For identification of phase I and II metabolites the workup and LC-HR-MS-MS method were the same as described above. ThermoFisher TraceFinder Clinical Research 3.2 software was used for data evaluation, as described by Helfer et al.
(submitted for publication).
Results and discussion

Identification of phase I and phase II metabolites by LC-HR-MS-MS
The structures of the urinary metabolites were deduced from their MS-MS spectra, by comparison with the spectra of the parent compounds. The fragmentation patterns were postulated on the basis of established rules [26] . The LC-HR-MS-MS spectra of DALT and its phase I metabolites are given in 
Proposed fragmentation patterns for identification of the phase I metabolites by LC-HR-MS-MS
For better description of positions, the basic structure was divided into three sections ( Fig. 1) , the aromatic ring (section 1), the ethyl spacer (section 2), and N,N-diallylamine (section 3). In the following discussion, important fragmentation patterns of the mass spectra of DALT, 5-MeO-DALT, and their phase I metabolites will be discussed in detail. All masses are the calculated exact masses.
DALT
The spectrum of the parent compound is given in ESM Either oxidation led to an N-oxide or both hydroxy groups were located on different substituents, although this possibility could be excluded by detection of the fragment ion with m/z 232.1206. Thus, the proposed metabolite structure seemed more consistent with an N-oxide. In general, N-oxides elute later than the parent compounds on reversed-phase columns. A corresponding metabolite representing allylic hydroxylation in section 3 was not detected. Of the hydroxy and dihydroxy metabolites detected (7-12 in ESM Fig. S1 ), the proposed N-oxide had the longest RT (4.5 min); the others were between 3.4 and 4.3 min. This seems to support this suggestion. Among hydroxy and dihydroxy metabolites, the trihydroxy metabolite could also be identified (13 in ESM Fig. S1 ). The mass spectrum showed a protonated molecule with m/z 289.1547 (C 16 . Both isomers had similar fragmentation patterns as arylhydroxy metabolites (7, 8 in ESM  Fig. S1 ), except for the allyl shift and an additional fragment ion with m/z 148.0757 (C 9 H 10 ON + ), indicative of arylhydroxylation of a methylindole species. It should be mentioned that this fragment ion differed from the fragment ion with m/z 148.0393 (C 8 H 6 O 2 N + ) detected for aryl dihydroxy metabolites (9, 10 in ESM Fig. S1 ).
5-MeO-DALT
The 5-MeO-DALT spectrum is given in ESM Fig. S2, ) and fragment ions similar to those identified for aryl trihydroxy DALT (13 in ESM Fig. S1 ). Thus, the two metabolically formed hydroxy groups were located in section 1. The spectrum of the Odemethyl N-dealkyl metabolite (2 in ESM Fig. S2) 
Proposed fragmentation patterns for identification of the phase II metabolites by LC-HR-MS-MS
In the following discussion, important fragmentation patterns of the mass spectra of DALT and 5-MeO-DALT phase II metabolites will be discussed. All masses are the calculated exact masses.
DALT
In general, the conjugates of the aryl monohydroxy metabolites furnished the same fragment ion as the underlying phase I metabolites, following conjugate losses of 79.9568 u for sulfates or 176.0321 u for glucuronides, with additional fragment ions with m/z 240.0325 (3S, 4S, 7S, 8S in ESM Fig. S3) for sulfates or at 336.1078 (3G, 4G, 7G, 8G in ESM Fig. S3 ) for glucuronides. These fragment ions represented the ethyl indole part (sections 1 + 2) with + 79.9568 u for sulfates or + 176.0321 u for glucuronides. In total, sulfates and glucuronides could be detected for two arylhydroxy isomers (7S, 8S, 7G, 8G in ESM Fig. S3 ) and two N-dealkyl arylhydroxy isomers (3S, 4S, 3G, 4G in ESM Fig. S3 ).
5-MeO-DALT
Sulfates and glucuronides were observed for alkylhydroxy (13S, 13G in ESM Fig. S4 ), arylhydroxy (14S, 14G in ESM Fig. S4 ), N-dealkyl alkylhydroxy (5S, 5G in ESM Fig. S4) metabolites, only glucuronides could be observed. Again, in addition to the fragment ions described for phase I metabolites, fragment ions with m/z 240.0325 (2S, 7S in ESM Fig. S4 ), 256.0274 (4S in ESM  Fig. S4 ), 270.0431 (5S, 6S, 13S, 14S in ESM Fig. S4 ), 336.1078 (2G, 7G in ESM Fig. S4 ), 352.1027 (4G, 8G, 9G in ESM Fig. S4 ), or 366.1183 (5G, 6G, 13G, 14G in ESM Fig. S4 ) were detected for sulfates or glucuronides of metabolites with hydroxy groups on the ethylindole moiety (sections 1 + 2).
Proposed metabolic pathways
According to the identified metabolites, metabolic pathways could be proposed as depicted in Fig. 2 for DALT and in Fig. 3 for 5-MeO-DALT.
DALT
Three hydroxylations were expected on the indole ring although only two could be detected (7, 8 in Fig. 2 ), most probably because of insufficient separation or low abundance of the third isomer. These monohydroxy metabolites were further hydroxylated to two isomeric dihydroxy metabolites (9, 10) and these finally to a trihydroxy metabolite (13) . Aliphatic hydroxylation in section 2 formed a precursor for the corresponding oxo metabolite (5) and the ring-rearranged metabolite (6) . N-dealkylation (2) and N-oxidation were also observed. The following combinations could be proposed from these observations: aromatic and aliphatic hydroxylation in section 2 (11) , N-oxidation with aliphatic hydroxylation in section 3 (12) , and Ndealkylation with aromatic hydroxylation (3, 4) . Glucuronidation and sulfation could be observed for both isomers of the arylhydroxylated metabolites with (3, 4) and without (7, 8 ) N-dealkylation.
5-MeO-DALT
The metabolic pathways were similar to those observed for DALT, including aromatic and aliphatic hydroxylation at different sites. Again, the indole ring was expected to bear three different hydroxylation sites although only one could be detected (14 in Fig. 3) , presumably for reasons similar to those mentioned above. These monohydroxy metabolites were further hydroxylated to two isomeric dihydroxy metabolites (16, 17) and finally to a trihydroxy metabolite (20) . Aliphatic hydroxylation in section 2 (13) formed a precursor for the corresponding two oxo metabolites (10, 11) and the ringrearranged metabolite (12) . N-Dealkylation (3), N-oxidation, or O-demethylation (7) were also observed. The following combinations could be proposed: aromatic and aliphatic (19) , N-oxidation with aliphatic mono or dihydroxylation in section 3 (18, 21) , N-dealkylation with aliphatic (5) or aromatic (6) hydroxylation, O-demethylation with aliphatic (9) or aromatic mono (8) or dihydroxylation (15) , with N-dealkylation (2), or Nd e a l k y l a t i o n w i t h a l i p h a t i c h y d r o x y l a t i o n ( 4 ) . Glucuronidation and sulfation was observed for alkyl (13) or arylhydroxy (14) metabolites, for O-demethyl (7) or N-dealkyl (3) metabolites, and for O-demethyl hydroxy metabolites (2, 4-6). For O-demethyl alkyl (9) or arylhydroxy metabolites (8) , only glucuronides were detected. If the pathways for both drugs are compared, it is obvious that one of the dihydroxy metabolites of DALT (9 in Fig. 2 ) is identical to the O-demethyl hydroxy metabolite of 5-MeO-DALT (8 in Fig. 3) . Similarly, the trihydroxy metabolite of DALT (13 in Fig. 2) is identical with the O-demethyl dihydroxy metabolite of 5-MeO-DALT (15 in Fig. 3 ), thus explaining identical spectra and retention times. The Odemethyl metabolite of 5-MeO-DALT (7 in Fig. 3 ) could be identical either with hydroxy metabolite 7 (Fig. 2 ) of DALT, with slightly different spectra and retention times, or with the undetected hydroxy metabolite.
Microsomal incubations of DALT and 5-MeO-DALT
Unfortunately, no human urine samples were available to enable confirmation that the metabolites in rat urine were also present in human urine. According to many former studies [16, 20, [27] [28] [29] [30] [31] [32] [33] [34] , combination of rat urine studies with incubation of new drugs with pHLM is a technique enabling good prediction of phase I metabolites for detection in human urine. Katagi et al. discussed transferability for other N,N-di-alkyl tryptamines [16] . After pHLM incubation, all phase I metabolites were detected for DALT, and metabolites 3, 5-7, 10-14, 16-18, and 21 ( Fig. 3) for 5-MeO-DALT. Therefore, it seems reasonable to assume that at least some of these metabolites might also be found in human urine.
For initial CYP activity screening, the metabolites were detected after incubation with individual CYPs. The relative involvement of the single CYPs in the metabolic pathways of DALT are listed in Table 1 ; those for 5-MeO-DALT are listed in Table 2 . The relative involvement of individual CYPs was defined in relation to the highest peak abundances during precursor ion monitoring of the metabolites formed. A CYP was defined as mainly involved if the corresponding relative peak abundance values were >50 %. According to these findings, the isoenzymes mainly involved in given metabolic steps were: for DALT, CYP3A4 in all types of hydroxylation, CYP2D6 in oxidation to the oxo metabolite, and CYP2C19 and CYP3A4 in N-dealkylations; for 5-MeO-DALT, CYP3A4 in all types of hydroxylation, CYP1A2 and CYP2D6 in oxidation to the oxo metabolites, CYP2C19 and CYP3A4 in Ndealkylations, and CYP2D6 in O-demethylations. Given that several CYP enzymes were involved in the metabolism of both drugs, one might expect CYP enzyme polymorphisms might be of minor toxicological relevance. Table 3 Targets for GC-MS SUSA monitoring of DALT, with molecular masses, the five most abundant fragment ions, their relative abundances, and retention indices according to Kovats [36] Compound 
, and LC-HR-MS-MS
The doses of 1 mg kg −1 BM administered to rats corresponded to low human single doses of approximately 10 mg scaled by the dose-by-factor approach of Sharma et al. [35] . As described above, these doses corresponded to the suggested dose for 5-MeO-DALT [9] [10] [11] . The corresponding urine samples were used for detectability studies. As already discussed, no human urine samples were available and thus, the main target for human urine analysis could not be elucidated. However, the SUSA cover all metabolites detected in rat urine including those identified in pHLM with their conjugates. From the experience gained in recent years, the possibility that consumption of these drugs and identification of their metabolites could be overlooked seems rather low. By use of GC-MS, only DALT could be screened for via the metabolites given in Table 3 with the corresponding fragment ions, their relative abundances, and their retention indices. 5-MeO-DALT and its metabolites could be monitored in rat urine only after high dose administration; it might, therefore, be detectable in overdose cases only. The corresponding GC-MS data have been published elsewhere [23] .
By use of LC-MS
